These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16187686)

  • 1. Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Sep; 6(9):874-8. PubMed ID: 16187686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure.
    Hingorany S; Frishman WH
    Cardiol Rev; 2011; 19(1):23-9. PubMed ID: 21135599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
    Tamargo J; Duarte J; Caballero R; Delpón E
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1039-47. PubMed ID: 20730699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
    Stasch JP; Hobbs AJ
    Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
    Dismuke WM; Sharif NA; Ellis DZ
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nitric oxide. The role of guanylate cyclase in its physiological effects].
    Severina IS
    Vopr Med Khim; 2002; 48(1):4-30. PubMed ID: 12068497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.
    Brioni JD; Nakane M; Hsieh GC; Moreland RB; Kolasa T; Sullivan JP
    Int J Impot Res; 2002 Feb; 14(1):8-14. PubMed ID: 11896472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts.
    Krieg T; Liu Y; Rütz T; Methner C; Yang XM; Dost T; Felix SB; Stasch JP; Cohen MV; Downey JM
    Eur Heart J; 2009 Jul; 30(13):1607-13. PubMed ID: 19406872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new class of soluble guanylate cyclase activators, generating nitric oxide].
    Riaposova IK; Grigor'ev NV; Severina IS
    Biokhimiia; 1994 Apr; 59(4):537-42. PubMed ID: 7912551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543.
    Watts JA; Gellar MA; Fulkerson MB; Kline JA
    Crit Care Med; 2011 Dec; 39(12):2700-4. PubMed ID: 21705882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice.
    Leiria LO; Silva FH; Davel AP; Alexandre EC; Calixto MC; De Nucci G; Mónica FZ; Antunes E
    J Urol; 2014 Feb; 191(2):539-47. PubMed ID: 24050894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
    Lasker GF; Pankey EA; Kadowitz PJ
    Physiology (Bethesda); 2013 Jul; 28(4):262-9. PubMed ID: 23817801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
    Evgenov OV; Pacher P; Schmidt PM; Haskó G; Schmidt HH; Stasch JP
    Nat Rev Drug Discov; 2006 Sep; 5(9):755-68. PubMed ID: 16955067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NO- and haem-independent soluble guanylate cyclase activators.
    Schmidt HH; Schmidt PM; Stasch JP
    Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAY 41-2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium-activated potassium current in pituitary GH cells.
    Liu YC; Wu SN
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1078-87. PubMed ID: 16445574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?
    Chirkov YY; Horowitz JD
    Pharmacol Ther; 2007 Nov; 116(2):287-305. PubMed ID: 17765975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.
    Kalk P; Godes M; Relle K; Rothkegel C; Hucke A; Stasch JP; Hocher B
    Br J Pharmacol; 2006 Jul; 148(6):853-9. PubMed ID: 16770325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.
    Stasch JP; Dembowsky K; Perzborn E; Stahl E; Schramm M
    Br J Pharmacol; 2002 Jan; 135(2):344-55. PubMed ID: 11815369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase: not a dull enzyme.
    Boerrigter G; Burnett JC
    Circulation; 2009 Jun; 119(21):2752-4. PubMed ID: 19451346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.